Article Information
PubMed
Published By
Print ISSN
Online ISSN
History
- Received for publication August 13, 2006
- Accepted for publication November 2, 2006
- Published online March 30, 2007.
Copyright & Usage
© 2007 by Society of Nuclear Medicine
Author Information
- Michael Gabriel 1 ,
- Clemens Decristoforo 1 ,
- Dorota Kendler 1 ,
- Georg Dobrozemsky 1 ,
- Dirk Heute 1 ,
- Christian Uprimny 1 ,
- Peter Kovacs 2 ,
- Elisabeth Von Guggenberg 1 ,
- Reto Bale 2 and
- Irene J. Virgolini 1
- 1Department of Nuclear Medicine, Innsbruck Medical University, Innsbruck, Austria; and 2Division of Diagnostic Radiology I, Department of Diagnostic Radiology, Innsbruck Medical University, Innsbruck, Austria
- For correspondence or reprints contact: Michael Gabriel, MD, Department of Nuclear Medicine, Innsbruck Medical University, Anichstrasse 35, 6020 Innsbruck, Austria. E-mail: michael.gabriel{at}uklibk.ac.at
Statistics from Altmetric.com
Cited By...
Article usage
Jump to section
Related Articles
Cited By...
- SNMMI Procedure Standard/EANM Practice Guideline for SSTR PET: Imaging Neuroendocrine Tumors
- Importance of PET with 68Ga-Labeled Somatostatin Analogs (perspective on "68Ga-DOTA-Tyr3-Octreotide PET in Neuroendocrine Tumors: Comparison with Somatostatin Receptor Scintigraphy and CT" J Nucl Med. 2007;48:508-518)
- Prognostic Value of 18F-FDG PET/CT in a Large Cohort of Patients with Advanced Metastatic Neuroendocrine Neoplasms Treated with Peptide Receptor Radionuclide Therapy
- Safety, tolerability and clinical implementation of 'ready-to-use 68gallium-DOTA0-Tyr3-octreotide (68Ga-DOTATOC) (SomaKIT TOC) for injection in patients diagnosed with gastroenteropancreatic neuroendocrine tumours (GEP-NETs)
- Improving Contrast and Detectability: Imaging with [55Co]Co-DOTATATE in Comparison with [64Cu]Cu-DOTATATE and [68Ga]Ga-DOTATATE
- 111In-Pentetreotide Scintigraphy Versus 68Ga-DOTATATE PET: Impact on Krenning Scores and Effect of Tumor Burden
- Multimodality imaging in carcinoid heart disease
- Twelve-Year Follow-up After Peptide Receptor Radionuclide Therapy
- CMKLR1-targeting peptide tracers for PET/MR imaging of breast cancer
- Sensitivity Comparison of 68Ga-OPS202 and 68Ga-DOTATOC PET/CT in Patients with Gastroenteropancreatic Neuroendocrine Tumors: A Prospective Phase II Imaging Study
- Safety, Biodistribution, and Radiation Dosimetry of 68Ga-OPS202 in Patients with Gastroenteropancreatic Neuroendocrine Tumors: A Prospective Phase I Imaging Study
- Current Concepts in 68Ga-DOTATATE Imaging of Neuroendocrine Neoplasms: Interpretation, Biodistribution, Dosimetry, and Molecular Strategies
- 68Ga-DOTATOC Imaging of Neuroendocrine Tumors: A Systematic Review and Metaanalysis
- Somatostatin Receptor 2-Targeting Compounds
- Localization of Unknown Primary Site with 68Ga-DOTATOC PET/CT in Patients with Metastatic Neuroendocrine Tumor
- The Impact of Somatostatin Receptor-Directed PET/CT on the Management of Patients with Neuroendocrine Tumor: A Systematic Review and Meta-Analysis
- Parametric Net Influx Rate Images of 68Ga-DOTATOC and 68Ga-DOTATATE: Quantitative Accuracy and Improved Image Contrast
- Head-to-Head Comparison of 64Cu-DOTATATE and 68Ga-DOTATOC PET/CT: A Prospective Study of 59 Patients with Neuroendocrine Tumors
- MIB-1 Index-Stratified Assessment of Dual-Tracer PET/CT with 68Ga-DOTATATE and 18F-FDG and Multimodality Anatomic Imaging in Metastatic Neuroendocrine Tumors of Unknown Primary in a PRRT Workup Setting
- 68Ga-DOTATATE PET/CT Interobserver Agreement for Neuroendocrine Tumor Assessment: Results of a Prospective Study on 50 Patients
- Comparison of the Impact of 68Ga-DOTATATE and 18F-FDG PET/CT on Clinical Management in Patients with Neuroendocrine Tumors
- 68Ga-DOTATOC PET/CT in Patients with Iodine- and 18F-FDG-Negative Differentiated Thyroid Carcinoma and Elevated Serum Thyroglobulin
- A Delphic consensus assessment: imaging and biomarkers in gastroenteropancreatic neuroendocrine tumor disease management
- Clinical Translation of a Click-Labeled 18F-Octreotate Radioligand for Imaging Neuroendocrine Tumors
- Safety and Efficacy of 68Ga-DOTATATE PET/CT for Diagnosis, Staging, and Treatment Management of Neuroendocrine Tumors
- Potential value of EUS in pancreatic surveillance of VHL patients
- Evaluation of the Efficacy of Targeted Imaging Agents
- Prospective Study of 68Ga-DOTATATE Positron Emission Tomography/Computed Tomography for Detecting Gastro-Entero-Pancreatic Neuroendocrine Tumors and Unknown Primary Sites
- Significance of a Single-Time-Point Somatostatin Receptor SPECT/Multiphase CT Protocol in the Diagnostic Work-up of Gastroenteropancreatic Neuroendocrine Neoplasms
- Appendiceal neuroendocrine neoplasms: diagnosis and management
- Prognostic Value of 68Ga-DOTANOC PET/CT SUVmax in Patients with Neuroendocrine Tumors of the Pancreas
- 64Cu-DOTATATE PET for Neuroendocrine Tumors: A Prospective Head-to-Head Comparison with 111In-DTPA-Octreotide in 112 Patients
- Increased 68Ga-DOTATATE Uptake in PET Imaging Discriminates Meningioma and Tumor-Free Tissue
- Can Complementary 68Ga-DOTATATE and 18F-FDG PET/CT Establish the Missing Link Between Histopathology and Therapeutic Approach in Gastroenteropancreatic Neuroendocrine Tumors?
- 68Ga-DOTATATE PET/CT, 99mTc-HYNIC-Octreotide SPECT/CT, and Whole-Body MR Imaging in Detection of Neuroendocrine Tumors: A Prospective Trial
- Preclinical Evaluation of a High-Affinity 18F-Trifluoroborate Octreotate Derivative for Somatostatin Receptor Imaging
- Evaluating digestive neuroendocrine tumor progression and therapeutic responses in the era of targeted therapies: state of the art
- PET/MR in Oncology: Non-18F-FDG Tracers for Routine Applications
- 18F-Fluorodihydroxyphenylalanine PET/CT in Patients with Neuroendocrine Tumors of Unknown Origin: Relation to Tumor Origin and Differentiation
- Promises of Cyclotron-Produced 44Sc as a Diagnostic Match for Trivalent {beta}--Emitters: In Vitro and In Vivo Study of a 44Sc-DOTA-Folate Conjugate
- Comparison of Response Evaluation in Patients with Gastroenteropancreatic and Thoracic Neuroendocrine Tumors After Treatment with [177Lu-DOTA0,Tyr3]Octreotate
- Comparison of 68Ga-DOTANOC and 68Ga-DOTATATE PET/CT Within Patients with Gastroenteropancreatic Neuroendocrine Tumors
- The Role of 68Ga-DOTATATE PET/CT in Suspected Neuroendocrine Tumors
- Unexpected Sensitivity of sst2 Antagonists to N-Terminal Radiometal Modifications
- Tumor Response Assessment to Treatment with [177Lu-DOTA0,Tyr3]Octreotate in Patients with Gastroenteropancreatic and Bronchial Neuroendocrine Tumors: Differential Response of Bone Versus Soft-Tissue Lesions
- Clinical PET of Neuroendocrine Tumors Using 64Cu-DOTATATE: First-in-Humans Study
- A Man with Abdominal Pain: Enough Evidence for Surgery?
- Nuclear medicine imaging of neuroendocrine tumours
- Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumours (NETs)
- The SNM Practice Guideline for Somatostatin Receptor Scintigraphy 2.0
- Radiopeptide Imaging and Therapy in Europe
- 68Ga-DOTATOC Versus 68Ga-DOTATATE PET/CT in Functional Imaging of Neuroendocrine Tumors
- Novel SDHD Gene Mutation (H102R) in a Patient With Metastatic Cervical Paraganglioma Effectively Treated by Peptide Receptor Radionuclide Therapy
- Treatment with Octreotide Does Not Reduce Tumor Uptake of 68Ga-DOTATATE as Measured by PET/CT in Patients with Neuroendocrine Tumors
- Nuclear medicine techniques for the imaging and treatment of neuroendocrine tumours
- 177Lu-DOTATATE Molecular Radiotherapy for Childhood Neuroblastoma
- Somatostatin Receptors as Targets for Nuclear Medicine Imaging and Radionuclide Treatment
- Incidence of Increased 68Ga-DOTANOC Uptake in the Pancreatic Head in a Large Series of Extrapancreatic NET Patients Studied with Sequential PET/CT
- 68Ga-DOTATOC PET/CT of Neuroendocrine Tumors: Spotlight on the CT Phases of a Triple-Phase Protocol
- Expression of somatostatin receptors, dopamine D2 receptors, noradrenaline transporters, and vesicular monoamine transporters in 52 pheochromocytomas and paragangliomas
- Diagnostics of Neuroendocrine Tumours
- Exendin-4-Based Radiopharmaceuticals for Glucagonlike Peptide-1 Receptor PET/CT and SPECT/CT
- The Role of 68Ga-DOTATATE PET in Patients with Neuroendocrine Tumors and Negative or Equivocal Findings on 111In-DTPA-Octreotide Scintigraphy
- 68Ga-DOTANOC PET/CT Clinical Impact in Patients with Neuroendocrine Tumors
- Somatostatin receptor-based imaging and therapy of gastroenteropancreatic neuroendocrine tumors
- Features of Carcinoid Heart Disease Identified by 2- and 3-Dimensional Echocardiography and Cardiac MRI
- A Comparison of 68Ga-DOTATATE and 18F-FDG PET/CT in Pulmonary Neuroendocrine Tumors
- 68Ga-DOTA-Tyr3-Octreotide PET for Assessing Response to Somatostatin-Receptor-Mediated Radionuclide Therapy
- Bone Metastases in Patients with Neuroendocrine Tumor: 68Ga-DOTA-Tyr3-Octreotide PET in Comparison to CT and Bone Scintigraphy
- The clinical value of [18F]fluoro-dihydroxyphenylalanine positron emission tomography in primary diagnosis, staging, and restaging of neuroendocrine tumors
- 99mTc-HYNIC-TOC Scintigraphy Is Superior to 131I-MIBG Imaging in the Evaluation of Extraadrenal Pheochromocytoma
- New Technologies for Human Cancer Imaging
- Tumor Receptor Imaging
- Utility of Radiolabeled Somatostatin Receptor Analogues for Staging/Restaging and Treatment of Somatostatin Receptor-Positive Pediatric Tumors
- Somatostatin Receptor Imaging in Patients with Neuroendocrine Tumors: Not Only SPECT?